Reid Robison, MD, MBA

Reid Robison, M.D., M.B.A. is CEO and co-founder of Tute Genomics. Dr. Robison is a board-certified psychiatrist, with fellowship training in both neurodevelopmental genetics and bioinformatics. After residency and fellowship training at the University of Utah, Dr. Robison joined as tenure track faculty where he co-directed a molecular genetics lab, studying the genetic basis of autism and other neurodevelopmental disorders, using next-generation sequencing technology. Dr. Robison has led over $10 million in pharmaceutical studies, and previously founded Clinical Methods, an innovative, data-driven Phase I-IV CNS trials site that was later acquired. Dr. Robison is also co-founder of Anolinx, a healthcare data analytics firm that was acquired in 2012.

Kai Wang, PhD

Dr. Kai Wang is President and co-founder of Tute Genomics. Dr. Wang is currently an Assistant Professor of Psychiatry and Preventive Medicine at the Zilkha Neurogenetic Institute, University of Southern California. He was trained as a molecular biologist at Peking University in China, and later became interested in Computational Biology and obtained a Ph.D. at the University of Washington. He completed postdoctoral training at the University of Pennsylvania and Children’s Hospital of Philadelphia, working on genomic analysis of human diseases. His current research focuses on next-generation sequencing data analysis, including the development of functional interpretation approaches, CNV calling methods and pathway-based association tests. He is the creator of ANNOVAR, the most widely used genome annotation software, which has been downloaded over 30,000 times, and cited in over 400 scientific articles. Dr. Wang has over 100 scientific publications to date.

Jim Oldham

Jim Oldham is Chief Technology Officer at Tute Genomics and has been working in the software industry for >10 years in specialized fields including finance, e-commerce, and big data. He is a member of the Data Science Association, and is leading the software architecture and web development efforts at Tute Genomics. He was previously at Fusion.io for 4 years through their initial public offering.

Tyler Richards

Tyler promotes an entrepreneurial spirit, and gives each business unit the power and accountability to make decisions tailored to specific partners and customers in Tute specific markets. Tyler has had experience in building multiple companies in his recent past focusing mainly in the software/tech industry. Richards is partially responsible for developing enterprise sales efforts here at Tute Genomics, as well as developing and maintaining relationships with Tute Genomics' partners. Richards has multiple years of sales and management experience, working with and generating revenue for successful public, private and start-up technology companies.

Lynn Dakoulas, MD

Lynn Dakoulas-Dobias, MD joined Tute in 2013 and brings with her a keen interest in in genomics and technology, as well as an extensive history in client relations spanning from civil engineering to healthcare. Lynn has worked on several genetics-based research projects in the past, including the familial patterns of suicide and Inflammatory Bowel Disease and has worked with the Utah Foundation for Biomedical Research in planning studies of the genetics of neuropsychiatric conditions. As a team member at Tute, she hopes to share her vision of the role for genomics in medicine, which to her means relaying the importance of embracing technology in the progress of healthcare, preventative medicine and research for physicians, scientists and individuals alike.

Mary Brown

Mary Brown is Director of Operations at Tute Genomics. Mary has an undergraduate degree in Psychology and previously worked as a research assistant in a cognitive neuroscience lab at the University of Utah. She was formerly Director of Operations at Timp Group, a Salt Lake City-based investment firm. Mary is excited to be a part of Tute and its groundbreaking methods to navigate the genome.

Dr. Mingfu Zhu, PhD

Dr. Mingfu Zhu leads the bioinformatics team at Tute Genomics. He is responsible for bioinformatics research and development in the company that lead to more accurate, robust and faster pipelines for analyzing and interpreting personal genomes. Dr. Zhu has extensive experience in analyzing genomic data. Before joining Tute, Dr. Zhu was an Assistant Professor in the Center for Human Genome Variation at Duke University Medical Center. His research interests lied in the multi-disciplinary field of computational genomics and statistical genetics. He developed ERDS, a tool for the detection of copy number variations using next generation sequence data. Dr. Zhu received postdoctoral training in bioinformatics at Duke University. He obtained a Ph.D. in mathematics from Clemson University and a BS in mathematics from University of Science and Technology of China.

Gray Petty, JD

Gray Petty is an intellectual property attorney with a masters degree and a JD from Lewis and Clark Law School. He completed a research internship at the University of Utah ecceles intitute and was formerly an adjunct professor of chemistry at Salt Lake Communicty College. He has worked in contracts at the University Utahs technology commercialization office and as a contract attorney for ARUP labratories specializing in patent discovery and analytics. Gray Petty is the lead in house counsel at Tute Genomics responsible for patents, contracts, and licenses.

Brendon Beebe

Brendon's Bio coming soon.

Dinesh Patel, PhD

Dr. Dinesh Patel is considered by many to be the father of biotechnology and pharmaceuticals in the Mountain West region. Dr. Patel is a managing director of Signal Peak Ventures (formerly vSpring Capital). From 1999 to 2004 he was the Founder, Chairman, President & CEO of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected nutraceutical products. Prior to vSpring, Dr. Patel was an active angel investor in over 20 biotech and technology companies. In 1999, Dr. Patel co-founded and was the Chairman of Salus Therapeutics, Inc., a biotechnology company focused on the research and development of nucleic acid-based therapeutics, including antisense and gene therapy drugs. From 1985 to 1999 Dr. Patel served as Co-Founder, Chairman of The Board of Directors and President & CEO of TheraTech, Inc., a biotechnology company which he took public and eventually sold for $350 million to Watson Pharmaceuticals. Dr. Patel serves on several non-profit boards, and has won numerous awards including 2006 Utah Technology Council Hall of Fame Inductee, 2006 Ellis Island Medal of Honor, US Small Business Administration’s Business Achiever Award, Scientific and Technology Award (State of Utah), Entrepreneur of the Year Award (Mountain West Venture Group) and Scientific and Technology Development Pioneer of Progress Award to name a few. Dr. Patel served as co-chair of Governor Huntsman’s transition team and is currently on the board of the Utah Policy Partnership (UPP). He is the Chairman of the USTAR (Utah Science Technology and Research Initiative) Governing Authority board. Dr. Patel currently serves as a member of the Tute Genomics Board of Directors.

Kenneth Ward, MD

Dr. Ward is internationally known in the field of medical genetics, and is among the few physicians in the country who are board-certified in four sub-specialties: OB/GYN, Maternal Fetal Medicine, Medical Genetics, and Molecular Genetics. As Professor of OB/GYN and Human Genetics, Dr. Ward founded and ran the University of Utah’s DNA Diagnostic Laboratory. He led the efforts to discover a number of human disease genes, including Total Anomalous Pulmonary Venous Return and Hereditary Multiple Exostosis, as well as genetic associations for several pregnancy-related diseases, including preeclampsia and pregnancy-induced hypertension. He is a Fellow of the American College of Obstetrics and Gynecology and a Founding Fellow of the American College of Medical Genetics. Dr. Ward received his medical degree at the University of Florida. Dr. Ward has also founded and directed several biotech companies including Taueret Laboratories providing genetic services, Axial Biotech focused on spinal disorders, and Affiliated Genetics providing DNA identification.

Robb Kunz

Robb Kunz is a Founder & CEO of several high-technology Companies, an Active Angel Investor, the Founder & Managing Partner of ventureblue Capital and Co-founder of BoomStartup, Utah’s Mentorship-driven investment program. As an Investor, he founded and created ventureblue Capital an early-stage high technology investment firm. He is an active Angel Investor as a member of the Olympus Angels Investors based in Salt Lake City, Utah and recently was acknowledge as one of the top 15 Angel Investors in the State of Utah for 2009 and 2010. He recently Co-founded and is Co-Managing Partner of BoomStartup, Utah’s Mentorship-driven Investment Program. He was recently selected as 2010 Investor Mentor of the Year in the State of Utah. As an Entrepreneur, his expertise and track record revolves around starting, launching & funding emerging Companies. He is a Senior Technology Executive with strong business strategy with hands-on execution capability. He is the Founder/CEO of KnowledgeBlue, an Open Source Systems Integrator and Software-as-a-Service (SaaS) firm. KnowledgeBlue was recently acknowledged as the 37th fastest growing Company in the State of Utah as part of the elite Utah100 group. He was recently acknowledged as one of the Top 100 Venture Entrepreneurs in the State of Utah as part of the v-Spring v100.

Caleb DesRosiers, JD

Caleb DesRosiers is a strategic advisor to Tute Genomics. Caleb advises not only Tute but large executive teams and investment committees on health care regulatory, payer, and government channel programs. Over the past decade, Caleb has been an active participant in the health care industry and serves on a number of boards and advisory boards, including Affinity Health Plan, Health eVillages, Physicians Interactive, and Primary Care Development Corporation. He is also a Strategic Advisor to Mansa Capital, a healthcare private equity firm.

Steven M. Lipkin, MD, PhD

Dr. Lipkin is a board certified Medical Geneticist with a focus on genetic testing for gastrointestinal diseases, including the Lynch Syndrome, Familial Adenomatous Polyposis, Hemochromatosis and Hereditary Pancreatic Cancer among others. He is an authority on cancer genetic syndromes, with a particular emphasis on hereditary Gastrointestinal cancer syndromes. He is the author of MAPP-MMR, a bioinformatic program that is used to interpret whether Lynch syndrome missense variants are deleterious muations or benign polymorphisms. He practices at Weill Medical College of Cornell University and New York-Presbyterian Hospital. He trained in Internal Medicince at Duke University and Medical Genetics at the National Human Genome Research Institute.

Liming Liang, PhD

Dr. Liang is a former Ph.D. student under the supervision of Dr. Gonçalo Abecasis at the University of Michigan. Liming is currently an assistant professor at Harvard School of Public Health. His research is focused on developing the computational and statistical tools required for understanding human genetic variation, with a particular focus on complex human disease. His applied projects currently focus on the genetic matching for case-control samples, whole genome simulator, genetics of asthma and eczema, and genome-wide association study of global gene expression. He also developed methods to analyze shotgun sequence data for the 1000 Genomes project.

Rong Chen, PhD

Dr. Chen is Director of Clinical Genome Informatics at Icahn Institute of Genetics and Multiscale Biology. He leads Personalized Cancer Therapy to sequence both DNA and RNA of cancer patients, identify and integrate somatic mutations, copy number aberrations, dis-regulated genes, and gene fusions to identify driver genes and pathways and suggest therapeutics. Prior to Mount Sinai, he led the collaborative efforts at Stanford University to drive personalized medicine and clinical diagnosis on Mendelian and complex diseases using genome and exome sequencing. Dr. Chen also helped launch a startup company Personalis, which won the VA's contract for the Million Veteran Genome project. Dr. Chen has a broad interest in translational bioinformatics and genome interpretation, and has published over 60 papers in Lancet, Cell, Nature Biotechnology, Nature Methods, PNAS, AJHG, PLoS Genetics, PLoS Computational Biology, Genome Research, Genome Biology, Genome Medicine, AJT, and Proteins. He holds numerous patents for software and databases on personalized medicine, diagnosis, and structure modeling.